FFFelix Frenkel

Felix Frenkel

*This is an algorithmically generated author record based on publicly available information.

Felix Frenkel has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

    by Cody A. Ramirez, Michelle Becker-Hapak, Kartik Singhal, David A. Russler-Germain, Felix Frenkel, Erica K. Barnell, Ethan D. McClain, Sweta Desai, Timothy Schappe, Onyinyechi C. Onyeador, et al.

    Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that “polyvalent” vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens. B-cell clonality was determined by the alignment of B-cell receptor (BCR) CDR3 regions from RNA-seq data, grouping at the protein level, and comparison with the BCR repertoire from healthy individuals using RNA-seq data. An average of 52 somatic mutations per patient (range, 2-172) were identified, and ≥2 (median, 15) high-quality neoantigens were predicted for 56 of 58 FL samples. The predicted neoantigen peptides were composed of missense mutations (77%), indels (9%), gene fusions (3%), and BCR sequences (11%). Building off of these preclinical analyses, we initiated a pilot clinical trial using personalized neoantigen vaccination combined with PD-1 blockade in patients with relapsed or refractory FL (#NCT03121677). Synthetic long peptide vaccines targeting predicted high-quality neoantigens were successfully synthesized for and administered to all 4 patients enrolled. Initial results demonstrate feasibility, safety, and potential immunologic and clinical responses. Our study suggests that a genomics-driven personalized cancer vaccine strategy is feasible for patients with FL, and this may overcome prior challenges in the field. This trial was registered at www.ClinicalTrials.gov as #NCT03121677.


  • Top Cited Papers
    Open Access

    Clinical trial links oncolytic immunoactivation to survival in glioblastoma

    by Alexander L. Ling, Isaac H. Solomon, Ana Montalvo Landivar, Hiroshi Nakashima, Jared K. Woods, Andres Santos, Nafisa Masud, Geoffrey Fell, Xiaokui Mo, Ayse S. Yilmaz, et al.

    Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM)1,2. Here we report the results of a first-in-human phase I trial in 41 patients with rGBM who were injected with CAN-3110—an oncolytic herpes virus (oHSV)3. In contrast to other clinical oHSVs, CAN-3110 retains the viral neurovirulence ICP34.5 gene transcribed by a nestin promoter; nestin is overexpressed in GBM and other invasive tumours, but not in the adult brain or healthy differentiated tissue4. These modifications confer CAN-3110 with preferential tumour replication. No dose-limiting toxicities were encountered. Positive HSV1 serology was significantly associated with both improved survival and clearance of CAN-3110 from injected tumours. Survival after treatment, particularly in individuals seropositive for HSV1, was significantly associated with (1) changes in tumour/PBMC T cell counts and clonal diversity, (2) peripheral expansion/contraction of specific T cell clonotypes; and (3) tumour transcriptomic signatures of immune activation. These results provide human validation that intralesional oHSV treatment enhances anticancer immune responses even in immunosuppressive tumour microenvironments, particularly in individuals with cognate serology to the injected virus. This provides a biological rationale for use of this oncolytic modality in cancers that are otherwise unresponsive to immunotherapy (ClinicalTrials.gov: NCT03152318).


  • Open Access

    Data from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    by Nikita Kotlov, Alexander Bagaev, Maria V. Revuelta, Jude M. Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina, et al.

    Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Transcriptomic and genetic characterization of DLBCL has increased the understanding of its intrinsic pathogenesis and provided potential therapeutic targets. However, the role of the microenvironment in DLBCL biology remains less understood. Here, we performed a transcriptomic analysis of the microenvironment of 4,655 DLBCLs from multiple independent cohorts and described four major lymphoma microenvironment categories that associate with distinct biological aberrations and clinical behavior. We also found evidence of genetic and epigenetic mechanisms deployed by cancer cells to evade microenvironmental constraints of lymphoma growth, supporting the rationale for implementing DNA hypomethylating agents in selected patients with DLBCL. In addition, our work uncovered new therapeutic vulnerabilities in the biochemical composition of the extracellular matrix that were exploited to decrease DLBCL proliferation in preclinical models. This novel classification provides a road map for the biological characterization and therapeutic exploitation of the DLBCL microenvironment.Significance:In a translational relevant transcriptomic-based classification, we characterized the microenvironment as a critical component of the B-cell lymphoma biology and associated it with the DLBCL clinical behavior establishing a novel opportunity for targeting therapies.This article is highlighted in the In This Issue feature, p. 1307

  • Open Access

    Supplementary Tables from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    by Nikita Kotlov, Alexander Bagaev, Maria V. Revuelta, Jude M. Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina, et al.

  • Open Access

    Supplementary Figures from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    by Nikita Kotlov, Alexander Bagaev, Maria V. Revuelta, Jude M. Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina, et al.

  • Open Access

    Supplementary Figures from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    by Nikita Kotlov, Alexander Bagaev, Maria V. Revuelta, Jude M. Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina, et al.

  • Open Access

    Supplementary Tables from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    by Nikita Kotlov, Alexander Bagaev, Maria V. Revuelta, Jude M. Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina, et al.

  • Open Access

    Data from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    by Nikita Kotlov, Alexander Bagaev, Maria V. Revuelta, Jude M. Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina, et al.

    Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Transcriptomic and genetic characterization of DLBCL has increased the understanding of its intrinsic pathogenesis and provided potential therapeutic targets. However, the role of the microenvironment in DLBCL biology remains less understood. Here, we performed a transcriptomic analysis of the microenvironment of 4,655 DLBCLs from multiple independent cohorts and described four major lymphoma microenvironment categories that associate with distinct biological aberrations and clinical behavior. We also found evidence of genetic and epigenetic mechanisms deployed by cancer cells to evade microenvironmental constraints of lymphoma growth, supporting the rationale for implementing DNA hypomethylating agents in selected patients with DLBCL. In addition, our work uncovered new therapeutic vulnerabilities in the biochemical composition of the extracellular matrix that were exploited to decrease DLBCL proliferation in preclinical models. This novel classification provides a road map for the biological characterization and therapeutic exploitation of the DLBCL microenvironment.Significance:In a translational relevant transcriptomic-based classification, we characterized the microenvironment as a critical component of the B-cell lymphoma biology and associated it with the DLBCL clinical behavior establishing a novel opportunity for targeting therapies.This article is highlighted in the In This Issue feature, p. 1307

  • Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma

    by Subhajit Ghosh, Jiayi Huang, Matthew Inkman, Jin Zhang, Sukrutha Thotala, Ekaterina Tikhonova, Natalia Miheecheva, Felix Frenkel, Ravshan Ataullakhanov, Xiaowei Wang, et al.

    Severe and prolonged lymphopenia frequently occurs in patients with glioblastoma after standard chemoradiotherapy and has been associated with worse survival, but its underlying biological mechanism is not well understood. To address this, we performed a correlative study in which we collected and analyzed peripheral blood of patients with glioblastoma ( n = 20) receiving chemoradiotherapy using genomic and immune monitoring technologies. RNA sequencing analysis of the peripheral blood mononuclear cells (PBMC) showed an elevated concentration of myeloid-derived suppressor cell (MDSC) regulatory genes in patients with lymphopenia when compared with patients without lymphopenia after chemoradiotherapy. Additional analysis including flow cytometry and single-cell RNA sequencing further confirmed increased numbers of circulating MDSC in patients with lymphopenia when compared with patients without lymphopenia after chemoradiotherapy. Preclinical murine models were also established and demonstrated a causal relationship between radiation-induced MDSC and systemic lymphopenia using transfusion and depletion experiments. Pharmacological inhibition of MDSC using an arginase-1 inhibitor (CB1158) or phosphodiesterase-5 inhibitor (tadalafil) during radiation therapy (RT) successfully abrogated radiation-induced lymphopenia and improved survival in the preclinical models. CB1158 and tadalafil are promising drugs in reducing radiation-induced lymphopenia in patients with glioblastoma. These results demonstrate the promise of using these classes of drugs to reduce treatment-related lymphopenia and immunosuppression.


  • Top Cited Papers

    Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

    by Alexander Bagaev, Nikita Kotlov, Krystle Nomie, Viktor Svekolkin, Azamat Gafurov, Olga Isaeva, Nikita Osokin, Ivan Kozlov, Felix Frenkel, Olga Gancharova, et al.